BriaCell's Bria-IMT leads to tumor regressions in Phase I/IIa for breast cancer

BriaCell Therapeutics Corp. (TSX-V:BCT; OTCQB:BCTXF) reported data from six patients with stage IV breast cancer in the Phase I/IIa WRI-GEV-007 trial showing that Bria-IMT (SV-BR-1-GM) led to tumor regression in two patients, including one with multiple metastatic lung lesions and one with cutaneous metastases. Bria-IMT was generally well tolerated with injection-site related erythema, induration and pruritus reported as the most common adverse events. Data were presented at the American Association for Cancer Research meeting in Chicago.

The single-arm, open-label, U.S. trial is enrolling about 40 patients to receive low-dose cyclophosphamide 2-3 days prior to Bria-IMT intradermal inoculation; followed by Bria-IMT split into four inoculations (two in the thighs and two in the upper back); followed by intradermal interferon (IFN) alpha 2b into the vaccination sites at two and four days post-Bria-IMT inoculation...